Alligator Bioscience
Clinical-stage biotech developing tumor-directed immuno-oncology antibody drugs.
ATORX | ST
Overview
Corporate Details
- ISIN(s):
- SE0000767188 (+8 more)
- LEI:
- 549300E15VI0MB7LXV19
- Country:
- Sweden
- Address:
- C/O Medicon Village, 223 81 Lund
- Sector:
- Manufacturing
Description
Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-12-10 08:31 |
Alligator Bioscience presenterar ALLIGATOR-FAB™ - ett nytt antikroppsbibliotek
|
Swedish | 84.7 KB | ||
| 2020-12-04 09:00 |
Godkänd IND för Alligator Biosciences CD40-antikropp mitazalimab
|
Swedish | 77.0 KB | ||
| 2020-12-04 09:00 |
Approved IND for Alligator Bioscience’s CD40-targeting antibody mitazalimab
|
English | 83.9 KB | ||
| 2020-11-20 13:30 |
Nomination Committee appointed in respect of AGM 2021 in Alligator Bioscience AB
|
English | 80.6 KB | ||
| 2020-11-20 13:30 |
Valberedning utsedd inför årsstämma 2021 i Alligator Bioscience AB
|
Swedish | 79.3 KB | ||
| 2020-11-16 14:00 |
Alligator Bioscience och Aptevo Therapeutics förbereder den bispecifika 4-1BBx5…
|
Swedish | 134.2 KB | ||
| 2020-11-16 14:00 |
Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4…
|
English | 132.5 KB | ||
| 2020-11-09 14:00 |
Alligator Bioscience presenterar på SITC 35th Annual Meeting
|
Swedish | 96.3 KB | ||
| 2020-11-09 14:00 |
Alligator Bioscience presents at the SITC 35th Annual Meeting
|
English | 95.0 KB | ||
| 2020-11-05 08:30 |
Alligator Bioscience presenterar mitazalimab på World Immunotherapy Congress 20…
|
Swedish | 111.4 KB | ||
| 2020-11-05 08:30 |
Alligator Bioscience presents the CD40 antibody mitazalimab at the World Immuno…
|
English | 99.3 KB | ||
| 2020-10-27 14:00 |
Förväntat terapeutiska dosnivåer uppnådda i fas I-studie med ATOR-1017
|
Swedish | 95.9 KB | ||
| 2020-10-27 14:00 |
Predicted therapeutic range dose levels reached in ATOR-1017 Phase I
|
English | 95.0 KB | ||
| 2020-10-22 08:00 | Swedish | 2.5 MB | |||
| 2020-10-22 08:00 | English | 2.5 MB |
Automate Your Workflow. Get a real-time feed of all Alligator Bioscience filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Alligator Bioscience
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Alligator Bioscience via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-28 | Peter Ostler | Other | Sell | 1,658,134 | 179,045.31 SEK |
| 2024-04-11 | Staffan Encrantz | Other | Sell | 44,108,581 | 47,196,181.67 SEK |
| 2022-10-27 | Sören Bregenholt Frederiksen | Other | Buy | 52,000 | 72,748.00 SEK |
| 2022-10-25 | Marie Svensson | Other | Buy | 12,000 | 16,632.00 SEK |
| 2022-08-19 | Sören Bregenholt Frederiksen | Other | Buy | 13,906 | 25,726.10 SEK |
| 2022-08-18 | Sören Bregenholt Frederiksen | Other | Buy | 31,094 | 56,911.35 SEK |
| 2022-05-31 | Peter Ostler | Other | Buy | 100,000 | 151,500.00 SEK |
| 2022-05-04 | Sören Bregenholt Frederiksen | Other | Buy | 30,000 | 50,895.00 SEK |
| 2022-05-02 | Sören Bregenholt Frederiksen | Other | Buy | 30,000 | 50,811.00 SEK |
| 2022-04-30 | Sören Bregenholt Frederiksen | Other | Buy | 30,000 | 51,171.00 SEK |
Peer Companies
